methyl 5-iodo-2,3-dimethoxybenzoate | 171805-85-9

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: methyl 5-iodo-2,3-dimethoxybenzoate
• 英文别名: methyl 5-iodo-2,3-dimethoxy-benzoate
• CAS: 171805-85-9
• 化学式: C₁₀H₁₁IO₄
• 分子量: 322.099
• InChiKey: IEDZLKKLXFZTNK-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.4
• 重原子数：
  15
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.3
• 拓扑面积：
  44.8
• 氢给体数：
  0
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  methyl 5-iodo-2,3-dimethoxybenzoate 在 sodium hydroxide 作用下， 以 四氢呋喃 、 水 为溶剂， 反应 20.0h， 以98%的产率得到2,3-二甲氧基-5-碘苯甲酸
  参考文献：
  名称：

  New Short Synthesis of (5)‐2,3‐Dimethoxy‐N‐[(1‐ethyl‐2‐pyrrolidinyl)methyl]‐5‐iodobenzamide: Dopamine D2 Receptor

  摘要：

  A new short and highly efficient synthesis of (5)-2,3-dimethoxy-N[(1-ethyl-2pyrrolidinyl)methyl]-5-iodobenzamide (epidepride, 1) from 3-methoxy-salicylaldehyde (o-vanillin, 2) and 3-methoxysalicyclic acid (6) was achieved by employing a new iodination method with iodine monochloride and iodine nitrate under basic conditions.

  DOI：

  10.1080/00397910701771199
• 作为产物：
  描述：

  3-甲氧基水杨酸 在 硫酸 、 chloroamine-T 、 potassium carbonate 、 sodium iodide 作用下， 以 N,N-二甲基甲酰胺 、 丙酮 为溶剂， 反应 37.0h， 生成 methyl 5-iodo-2,3-dimethoxybenzoate
  参考文献：
  名称：

  Synthesis and 5-HT-3 receptor binding activity of 5-[125I]iodo-2,3-dimethoxy-N-(1-azabicyclo[2.2.2]oct-3-yl)benzamide and its 5-halogen-2-alkoxyl homologues

  摘要：

  (S)-5-Iodo-2,3-dimethoxy-N-(1-azabicyclo[2.2.2]oct-3-yl)benzamide (MIZAC) was prepared from 5-iodo-2,3-dimethoxybenzoyl chloride and (S)-3-aminoquinuclidine. [I-125]Iodode-stannylation of its corresponding 5-tri-n-butyltin derivative gave [I-125]-MIZAC at 1800 Ci/mmol. Binding of [I-125]-MIZAC in rat entorhinal cortex revealed a K-D of 1.37 +/- 0.21 nM. A series of racemic 2-O-alkyl derivatives of MIZAC were prepared and 5-HT-3 receptor affinities were determined by inhibition of [I-125]-MIZAC binding. Optimal affinity for the receptor was obtained with small, electron-withdrawing substituents in the aromatic 5-position and with bulky substituents in the 3-position. [I-125]-MIZAC is a selective radioligand useful for in vitro identification of the 5-HT-3 receptor.

  DOI：

  10.1016/s0223-5234(97)81676-5

文献信息

• New COMT inhibitors for the treatment of depression and impaired cognition
  申请人：Diederich Francois

  公开号：US20050137162A1

  公开（公告）日：2005-06-23

  The present invention relates to compounds of formula I wherein R 1 is as defined in the specification and to esters thereof which are hydrolyzable under physiological conditions and to the pharmaceutically acceptable salts thereof. The compounds of the invention are inhibitors of COMT and, thus, are useful for the treatment of diseases for which COMT inhibition is beneficial. The invention further relates to the treatment, control, or prevention of diseases such as depression, schizophrenia, Parkinson's disease, and to improve cognition.

  本发明涉及以下式I的化合物 其中R 1 如规范中定义 以及在生理条件下可水解的酯及其药用可接受的盐。本发明的化合物是COMT的抑制剂，因此对于COMT抑制有益的疾病的治疗是有用的。本发明还涉及治疗、控制或预防抑郁症、精神分裂症、帕金森病以及改善认知的疾病。
• Synthesis and Biological Evaluation of Potent Bisubstrate Inhibitors of the Enzyme CatecholO-Methyltransferase (COMT) Lacking a Nitro Group
  作者：Ralph Paulini、Christian Lerner、François Diederich、Roland Jakob-Roetne、Gerhard Zürcher、Edilio Borroni

  DOI：10.1002/hlca.200690179

  日期：2006.9

  activity despite the lack of a NO2 substituent on the catechol moiety. Their synthesis takes advantage of a convergent approach, in which a series of functionalized catechol intermediates is prepared (Schemes 2–7) and coupled to a common adenosine-derived allylic amine building block (Scheme 8). Biological activities of the newly synthesized inhibitors, determined by in vitro enzymatic assay and kinetic

  抑制儿茶酚O-甲基转移酶（COMT）代表了一种可行的策略，可调节儿茶酚胺神经递质或其前体的分解代谢，并且在帕金森氏病的治疗中引起了极大的兴趣。本文中，我们报道了由硝基取代的配体1（K i  = 28 nM，表1）衍生的新一代有效的COMT双底物抑制剂的开发，尽管邻苯二酚上没有NO 2取代基，该抑制剂仍具有很高的生物活性。部分。它们的合成利用会聚方法的优势，其中制备了一系列功能化的邻苯二酚中间体（方案2–7））并偶联至常见的腺苷衍生的烯丙基胺结构单元（方案8）。通过体外酶促测定和动力学研究确定的新合成抑制剂的生物活性清楚地表明，双底物抑制剂的高抑制能力与邻苯二酚OH基团的p K a不相关。发现通过联芳基型连接与邻苯二酚连接的芳族残基最大程度地受益于与该酶的其他有利疏水相互作用，因此是1中NO 2基团的优选替代物。竞争性动力学抑制机制（图2）相对于所述辅因子结合位点被证实在所有情况下，支撑用于抑制剂双底物抑制模式2
• COMT inhibitors for the treatment of depression and impaired cognition
  申请人：Hoffmann-La Roche Inc.

  公开号：US07319101B2

  公开（公告）日：2008-01-15

  The present invention relates to compounds of formula I wherein R1 is as defined in the specification and to esters thereof which are hydrolyzable under physiological conditions and to the pharmaceutically acceptable salts thereof. The compounds of the invention are inhibitors of COMT and, thus, are useful for the treatment of diseases for which COMT inhibition is beneficial. The invention further relates to the treatment, control, or prevention of diseases such as depression, schizophrenia, Parkinson's disease, and to improve cognition.

  本发明涉及公式I的化合物，其中R1如规范中所定义，并涉及在生理条件下可水解的酯及其药学上可接受的盐。本发明的化合物是COMT的抑制剂，因此对于COMT抑制有益的疾病的治疗非常有用。本发明还涉及治疗、控制或预防抑郁症、精神分裂症、帕金森病以及改善认知能力的疾病。
• Fluorinated and iodinated dopamine agents: D2 imaging agents for PET and SPECT
  作者：S. Chumpradit、M. P. Kung、J. Billings、R. Mach、H. F. Kung

  DOI：10.1021/jm00054a005

  日期：1993.1

  A novel series of dual-labeling D2 dopamine agents (labeled with either F-18 or I-123 for PET or SPECT imaging, respectively) was investigated. Two desired fluorinated and iodinated dopamine agents, FIDA1, (S)-(-)-2-(2-fluoroethoxy)-5-iodo-3-methoxy-N-[(1-ethyl-2-pyrrolidinyl)methyl]benzamide, and FIDA2, (R)-(+)-2,3-dimethoxy-5-iodo-N-[(1-(4'-fluorobenzyl)-2-pyrrolidinyl)methyl]benzamide, were synthesized. Both compounds displayed high affinity to the D2 receptor of rat striatal membrane preparations (K(d) = 0.13 and 0.02 nM for FIDA1 and FIDA2, respectively). The biodistribution study in rats exhibited high localization in the striata of the brain with the striatum/cerebellum ratio reaching 29.3 and 13.1 at 1 h post iv injection for FIDA1 and FIDA2, respectively. Imaging studies with [F-18]- and [I-123]FIDA2 in monkeys, with PET and SPECT, respectively, showed comparable high selective striatal uptake. These results suggest that they are potentially useful D2 dopamine receptor imaging agents for PET and SPECT.
• COMT INHIBITORS
  申请人：F.HOFFMANN-LA ROCHE AG

  公开号：EP1697394B1

  公开（公告）日：2007-03-21